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Vagal Nerve Stimulation Markedly Improves Long-Term
Survival After Chronic Heart Failure in Rats
Meihua Li, MS; Can Zheng, PhD; Takayuki Sato, MD; Toru Kawada, MD;
Masaru Sugimachi, MD; Kenji Sunagawa, MD
Background—Diminished cardiac vagal activity and higher heart rate predict a high mortality rate of chronic heart failure
(CHF) after myocardial infarction. We investigated the effects of chronic electrical stimulation of the vagus nerve on
cardiac remodeling and long-term survival in an animal model of CHF after large myocardial infarction.
Methods and Results—Two weeks after the ligation of the left coronary artery, surviving rats were randomized to vagal-
and sham-stimulated groups. Using an implantable miniature radio-controlled electrical stimulator, we stimulated the
right vagal nerve of CHF rats for 6 weeks. The intensity of electrical stimulation was adjusted for each rat, so that the
heart rate was lowered by 20 to 30 beats per minute. The treated rats had significantly lower left ventricular end-diastolic
pressure (17.15.9 versus 23.54.2 mm Hg, P0.05) and higher maximum dp/dt of left ventricular pressure
(4152237 versus 2987192 mm Hg/s, P0.05) than the untreated rats. Improvement of cardiac pumping function
was accompanied by a decrease in normalized biventricular weight (2.750.25 versus 3.140.22 g/kg, P0.01).
Although the 140-day survival of the untreated group was only half, vagal stimulation markedly improved the survival
rate (86% versus 50%, P0.008). Vagal stimulation therapy achieved a 73% reduction in a relative risk ratio of death.
Conclusions—Vagal nerve stimulation markedly improved the long-term survival of CHF rats through the prevention of
pumping failure and cardiac remodeling. (Circulation. 2004;109:120-124.)
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Acute myocardial infarction1 occurs when blood supply topart of the heart muscle is severely reduced or stopped.
Survivors after large myocardial infarction have a high risk
for chronic heart failure (CHF), with poor prognosis. CHF is
a clinical syndrome that is initiated by cardiac dysfunction
and followed by activation of compensatory mechanisms
such as the sympathoadrenal and renin-angiotensin-aldoste-
rone systems. Apparently, activation of compensatory mech-
anisms during the early phase of CHF helps the heart
compensate for deteriorating pumping function. However,
excessive sustained activation has deleterious effects on
cardiac function. Once such an excessive activation, on the
contrary, worsens cardiac function, it triggers further activa-
tion of those compensatory mechanisms, which, in turn,
further deteriorates cardiac function. This positive feedback
mechanism leads the heart to decompensatory cardiac remod-
eling and failure at the end stage. Therefore, the maladapta-
tion process is a key of pathophysiology of CHF.
In the maladaptation process, the cardiac autonomic ner-
vous system2,3 also plays an important role. Clinical evidence
from the Autonomic Tone and Reflexes After Myocardial
Infarction study (ATRAMI)4 and the Cardiac Insufficiency
BIsoprolol Study II (CIBIS II)5 indicates that diminished
cardiac vagal activity and increased heart rate predict a high
mortality rate of CHF. Based on this body of knowledge, it
would be logical to clarify whether augmentation of vagal
activity prevents cardiac remodeling and death. On the
occurrence of life-threatening arrhythmias in acute ischemia,
the effect of vagal stimulation has been reported to prevent
ventricular fibrillation in dogs.6 The antianginal effect of
vagal stimulation has been also shown in patients with
coronary artery disease.7 However, its effect on CHF remains
unknown. Therefore, in the present study, we examined the
effects of vagal stimulation on cardiac remodeling after large
myocardial infarction and on the long-term prognosis of CHF
in rats.
Methods
Experimental Heart Failure
The care and use of the animals were in strict accordance with the
guiding principles of the Physiological Society of Japan. Left
ventricular myocardial infarction was induced by coronary artery
ligation in 8-week-old male Sprague-Dawley rats (SLC, Hamamatsu,
Japan). The mortality rate in animals with myocardial infarction was
60% within the first 24 hours. One week later, we checked the
infarct size by echocardiography (SSA-380A, Toshiba), as described
previously.8 The rats with infarcted area40% of the left ventricular
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wall were enrolled in the present study. In sham-operated rats, we
loosely tied a suture to avoid coronary artery occlusion. We
confirmed the infarct size by postmortem examination.
Vagal Nerve Stimulation
To stimulate the vagal nerve and to monitor blood pressure and heart
rate in freely moving rats, we developed a remote system controlled
by a computer (Figure 1). The computer commands an implantable
and radio-controlled pulse generator (ISE1010C, Unimec) to stimu-
late the vagal nerve while sensing blood pressure and heart rate
through an implantable transmitter (TA11PA-C40, Data Sciences
International). The miniature pulse generator and transmitter were
subcutaneously implanted in the abdomen at 7 days after myocardial
infarction. A pair of Teflon-coated stainless steel wires for electrical
stimulation was looped around the right vagal nerve in the neck; a
Teflon tube for blood pressure recording was placed in the abdom-
inal aorta.
Experimental Protocols
At 14 days after myocardial infarction, the survivors were random-
ized into groups treated with sham and active stimulation. In the
actively treated group, we stimulated the vagal nerve with electrical
rectangular pulses of 0.2-ms duration at 20 Hz for 10 seconds every
minute for 6 weeks. The electrical current of pulses was adjusted for
each rat, so that the heart rate was lowered by 20 to 30 beats per
minute. This resulted in the ranges of 0.1 to 0.13 mA. Mean blood
pressure and heart rate were recorded every minute for 6 weeks. In
a preliminary study, we confirmed that the chronic vagal stimulation
at this intensity did not alter feeding behavior and did not evoke any
signs of pain reaction such as an increase in plasma epinephrine
level.
Hemodynamic and Remodeling Study
To evaluate the effect of vagal stimulation on cardiac remodeling, at
the end of the 6-week stimulation period we measured hemodynam-
ics and heart weights of sham-operated and sham-stimulated rats,
untreated CHF rats, and treated CHF rats. Anesthesia was maintained
through the use of 1.2% halothane during surgical procedures and
0.6% halothane during data recording. Left ventricular and arterial
pressures were measured with a 2F catheter-tipped micromanometer
(SPC-320, Millar Instruments). Pressure signals were digitized at a
rate of 1 kHz for 5 minutes. After hemodynamic measurement, the
heart was excised for subsequent determination of infarct size.
Prognosis and Neurohormone Study
To examine the effect of 6-week vagal stimulation on prognosis, we
observed a 20-week survival rate in treated and untreated CHF rats.
Because of the life of the battery of the implantable pulse generator,
the treatment period was limited to 6 weeks. Each cage was
inspected daily for the rat that had died. The heart was removed from
the dead animal for subsequent determination of infarct size.
At the end of the observation period, blood for neurohormone
assays was sampled. The surviving rat was placed in a glass jar,
where it inspired a mixture of 1.2% halothane in oxygen-enriched air
for 5 to 10 minutes. To avoid the modification of neurohumoral
states by invasive manipulation, immediately after the induction of
anesthesia, we quickly collected 3 mL of a blood sample from the
left ventricular cavity through a transthoracic approach without
measuring hemodynamics. After blood sampling, the heart was
excised for subsequent determination of infarct size.
Plasma concentrations of norepinephrine were measured by high-
performance liquid chromatography with electrochemical detection.
Plasma levels of brain natriuretic peptide were determined by
radioimmunoassay.
Determination of Infarct Size
As described previously,9 the right ventricle and the left ventricle
including the interventricular septum were dissected, separated, and
weighted. The heart was fixed in 10% buffered formalin. The left
ventricle was cut from apex to base into 4 transverse slices. Sections
4 m thick were cut and stained by Masson trichrome method.
Histological images were digitized through a frame grabber and
analyzed. Infarct size was calculated from the 4 slices by dividing the
sum of the endocardial lengths of infarcted regions by the sum of the
total endocardial circumferences.
Statistical Analysis
For data of the hemodynamic and remodeling study, differences
among 3 groups were tested by ANOVA, with a Scheffé multiple
comparison test. Differences in heart rates before and during treat-
ment in each group were examined by a 1-way ANOVA with
repeated measures, followed by a post hoc Dunnett test.
For a neurohormonal data, differences between two groups were
examined by a Mann-Whitney U test. Survival data are presented as
Kaplan-Meier curves; the effect of treatment on 140-day survival
was analyzed by a Fisher exact test. Differences were considered
significant at a value of P0.05.
Figure 2. Effects of 6-week vagal nerve stimulation on 24-hour
average of heart rate of sham-operated (SO-SS, ▫, n9) rats
treated with sham stimulation, CHF rats treated with sham
(CHF-SS, , n13), and vagal stimulation (CHF-VS, , n11).
Data are expressed as meanSEM. *P0.05 from SO-SS
group; †P0.05 from CHF-SS group; ‡P0.05 from pretreat-
ment values of each group.
Figure 1. Neural interface approach to stimulate the vagal
nerve. While monitoring heart rate through an implantable trans-
mitter, a remote control system adjusted the intensity of electri-
cal pulses of an implantable miniature radio-controlled electrical
stimulator.
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Results
Hemodynamic and Remodeling Study
Although CHF rats (untreated, n13; treated, n11) had a
higher heart rate than sham-operated rats (n9) before the
treatment, vagal stimulation significantly slowed the heart
rate of CHF rats (Figure 2). The difference in heart rate
between untreated and treated CHF rats reached 40 beats
per minute at the end of treatment (P0.05). CHF rats had
significantly lower blood pressure, but the vagal stimulation
did not affect blood pressure during the 6-week treatment
period (Table).
When compared with sham-operated rats, untreated CHF rats
had low blood pressure (Figure 3a), high left ventricular end-di-
astolic pressure (LVEDP) (Figure 3b), a depressed maximum
dp/dt of left ventricular pressure (LVdp/dtmax) (Figure 3c), and
an increased heart weight (Figure 3d). On the other hand, CHF
rats treated with vagal nerve stimulation had significantly lower
LVEDP (17.15.9 versus 23.54.2 mm Hg, P0.05) and
higher LVdp/dtmax (4152237 versus 2987192 mm Hg/s,
P0.05) than untreated CHF rats. Improvement of pumping
function in treated CHF rats was accompanied by a significant
decrease in normalized biventricular weight (2.750.25 versus
3.140.22 g/kg, P0.01). There was no significant difference
in infarct size between treated and untreated CHF rats (537%
versus 536%).
Prognosis and Neurohormone Study
Although 60 rats with CHF after large myocardial infarction
were enrolled in the prognosis study, 8 of the 30 rats assigned
to the treated group were excluded from the results because of
the breaking down of electrode wires during vagal stimula-
tion for 6 weeks. Vagal nerve stimulation markedly sup-
pressed the mortality rate of CHF rats (Figure 4); there were
only 3 deaths among the 22 treated rats versus 15 deaths
among the 30 untreated rats (14% versus 50%, P0.008).
Vagal stimulation therapy achieved a 73% reduction in a
relative risk ratio of death.
Shown in Figure 5, improvement of survival in treated
CHF rats was accompanied by a significant decrease in
normalized biventricular weight (2.630.38 versus
3.170.42 g/kg, P0.01). When compared with untreated
CHF rats, treated CHF rats had lower levels of plasma
norepinephrine (426102 versus 1182260 pg/mL,
P0.01) and brain natriuretic peptide (25131 versus
36382 pg/mL, P0.01). There was no significant differ-
ence in infarct size between treated and untreated CHF rats
(548% versus 537%).
Discussion
The prognosis of patients with CHF is still poor, even though
various therapeutic approaches with a -adrenergic receptor
Mean Blood Pressure (mm Hg)
Group Before
Weeks After Stimulation
1 2 3 4 5 6
SO-SS 1042 1043 1043 1033 1023 1022 1043
CHF-SS 833* 836* 836* 839* 859* 837* 816*
CHF-VS 8510* 825* 827* 817* 807* 826* 837*
SO-SS indicates sham-operated rats treated with sham stimulation (SS); CHF-SS, CHF rats treated
with sham stimulation; CHF-VS, CHF rats treated with vagal stimulation. Values are meanSD of the
24-hour average of mean blood pressure.
*P0.01 from SO-SS group.
Figure 3. Effects of vagal nerve stimulation on a, mean blood
pressure; b, LVEDP; c, maximum dp/dt of left ventricular pres-
sure (LVdP/dtmax); d, biventricular weight normalized by body
weight in sham-operated (SO-SS, hatched bar, n9) rats
treated with sham stimulation, CHF rats treated with sham
(CHF-SS, open bar, n13), and vagal stimulation (CHF-VS,
closed bar, n11). Assessment was made at the end of 6-week
treatment. Data are expressed as meanSD. *P0.05;
‡P0.01.
Figure 4. Effects of vagal nerve stimulation on survival curves of
CHF rats treated with sham (broken line, n30) and vagal stim-
ulation (solid line, n22). Treatment started 14 days after coro-
nary artery ligation. Vagal stimulation significantly (P0.008)
improved survival rate.
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blocker,10,11 angiotensin-converting enzyme inhibitor,12 an-
giotensin-receptor blocker,13 aldosterone antagonist,14 and
implantable defibrillator15 are currently available. Therefore,
more effective modality of therapy is expected.
The present results indicate that vagal nerve stimulation
markedly improved the long-term survival of CHF rats
through prevention of the progression of pumping failure and
cardiac remodeling. The main objective of the present study
was to test the working hypothesis that long-term vagal
stimulation can improve survival of CHF rats after large
myocardial infarction, not to clarify the mechanism. How-
ever, some considerations on this issue are warranted.
It is conceivable that vagal stimulation may effectively
sever the vicious cycle leading to death through an inhibitory
effect on presynaptic norepinephrine releases and suppressive
effects on adrenergic signaling cascade through G-protein
interactions.16 In human hearts as well as those of several
other species, muscarinic receptors are predominantly of the
M2-subtype, which couples through a pertussis toxin–sensi-
tive GI protein to inhibit adenyl cyclase. In the atrium,
stimulation of muscarinic M2 receptors causes direct negative
inotropic and chronotropic effects; in the ventricle, on the
other hand, the negative inotropic effect can be only achieved
when the basal level of cAMP is elevated by -adrenoceptor
agonists. These mechanisms are known as accentuated
antagonism.
Vagal stimulation is also postulated to improve ventricular
efficiency by slowing heart rate.17 Burkhoff et al18 showed
that the ventricular efficiency, that is, the ratio of ventricular
stroke work to ventricular oxygen consumption, is adjusted to
be maximal under physiological conditions and that the
efficiency of the failing heart is more sensitive to changes in
heart rate than that of the normal heart. Prevention of
tachycardia after myocardial infarction by vagal stimulation
would optimize the efficiency of the failing heart and thus
protect the heart against remodeling.
Apparently, vagal efferent stimulation is considered to act
on the ventricle of CHF like a -adrenergic blocker. How-
ever, in rats, -blockade therapy rather failed to exert a
beneficial effect on the cardiac remodeling or hemodynamics
after myocardial infarction (for review, see Gaballa and
Goldman19). Litwin et al20 showed that chronic propranolol
treatment did not improve cardiac remodeling and worsened
pumping function in rats with postinfarction CHF. Wei et al21
also demonstrated that metoprolol deteriorated ventricular
remodeling in CHF rats. Therefore, in addition to antagonism
against sympathetic effects, unique actions of vagal stimula-
tion would be important in providing the favorable outcome
for CHF rats. A facilitatory effect of vagal stimulation on
nitric oxide release from the coronary endothelium could also
have an antiremodeling action through improvement of viable
myocardial conditions.22
In addition to the effects of electrical stimulation of vagal
efferents on the heart, vagal afferent effects7,23 are also
considered because afferent stimulation would evoke cardio-
pulmonary reflex and modulate neuronal activity in several
hypothalamic nuclei involved in cardiovascular regulation.
As shown in Figure 5c, vagal stimulation lowered the plasma
norepinephrine level. Therefore, vagal stimulation therapy
would terminate the vicious circle of maladaptation in CHF
through the suppression of chronic excessive activation of the
sympathetic nervous system.24,25
A more recent study by Guarini et al26 has shown that
efferent vagal fiber stimulation blunts activation of nuclear
factor-B in the liver through nicotinic receptors and then
reduces the hepatic production and the plasma level of tumor
necrosis factor- during acute hemorrhagic shock. It has been
reported that these factors are also involved in cardiac
remodeling and the poor prognosis of CHF.27 Therefore, the
hepatic effect of vagal stimulation would prevent cardiac
remodeling and improve survival of CHF.
It is also noted that short-term vagal stimulation for 6
weeks after myocardial infarction prevented long-term car-
diac remodeling (Figure 5a) and improved the long-term
survival. There may be a critical period during which short-
term treatment against cardiac dysfunction and remodeling
will ensure the long-term survival of CHF.
A pioneer work by Pfeffer et al28 examined the effect of
long-term therapy with captopril in CHF rats after myocardial
infarction. As well as vagal stimulation in the present study,
oral captopril administration started at 14 days after ligation
of the left coronary artery. Pfeffer et al observed 1-year
survival and found that the median survival was 146 and 181
days for untreated and treated CHF rats with large infarcts,
respectively. Thus, the survival curve of untreated CHF rats
with large infarcts in their study was quite similar to our result
of untreated CHF rats. On the other hand, the effect of
captopril on survival in CHF rats with large infarcts appeared
to be much different from that of vagal stimulation. Approx-
imately 40% of captopril-treated CHF rats with large infarcts
died at 140 days; vagal stimulation reduced the mortality rate
to 20%. Therefore, vagal stimulation therapy may be
promising for severe CHF after large myocardial infarction.
Figure 5. Comparison of biventricular weight normalized by
body weight (a), infarct size (b), and plasma levels of norepi-
nephrine (c) and brain natriuretic peptide (d) in CHF rats treated
with sham stimulation (SS) and vagal stimulation (VS). Each
value in parentheses indicates number of animals in each group.
*P0.01.
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Limitations
The beneficial effects of vagal stimulation on cardiac func-
tion, remodeling, and survival of CHF rats were shown in the
present study. However, its safety and adverse effects remain
to be unclear. The appropriate protocol of treatment is also
still unsettled and should be investigated. To establish the
therapeutic strategy shown in this study, large-scale, long-
term trials of vagal nerve stimulation with an animal model of
CHF are required.
Clinical Implications
Our previous studies9,29 indicated that a pharmacological
intervention in the central nervous system of CHF rats
prevented the progression of cardiac dysfunction and remod-
eling. The therapeutic modality used in the present study also
brought a favorable prognosis of CHF by manipulation of
autonomic tone through vagal efferent and/or afferent mech-
anisms. We therefore propose the neural interface approach to
optimize cardiac autonomic tone for the treatment of CHF.
Technologies to materialize this neural interface strategy30
using totally implantable miniaturized systems are readily
available.31,32
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